



REVIEW ARTICLE

Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid^{☆,☆☆}



E. Peña^{a,*}, M. Mata^b, L. López-Manzanares^c, M. Kurtis^d, M. Eimil^e,
J.C. Martínez-Castrillo^f, I. Navas^g, I.J. Posada^h, C. Prietoⁱ, C. Ruíz-Huete^j, L. Vela^k,
B. Venegasⁱ, on behalf of the movement disorder study group of the Neurological
Association of Madrid

^a Servicio de Neurología, Hospital Sanitas La Moraleja, Madrid, Spain

^b Servicio de Neurología, Hospital Infanta Sofía, Madrid, Spain

^c Servicio de Neurología, Hospital de La Princesa, Madrid, Spain

^d Servicio de Neurología, Hospital Ruber Internacional, Madrid, Spain

^e Servicio de Neurología, Hospital de Torrejón, Madrid, Spain

^f Servicio de Neurología, Hospital Ramón y Cajal, Madrid, Spain

^g Servicio de Neurología, Hospital Fundación Jiménez Díaz, Madrid, Spain

^h Servicio de Neurología, Hospital 12 de Octubre, Madrid, Spain

ⁱ Servicio de Neurología, Hospitales Rey Juan Carlos, Infanta Elena y Villalba, Madrid, Spain

^j Servicio de Neurología, Clínica del Rosario, Madrid, Spain

^k Servicio de Neurología, Hospital Fundación Alcorcón, Madrid, Spain

Received 10 November 2015; accepted 1 February 2016

Available online 11 March 2018

KEYWORDS

Antidepressants;
Depression;
Anxiety;
Parkinson's disease;
Side effects;
Mechanisms of action

Abstract

Introduction: Although antidepressants are widely used in Parkinson's disease (PD), few well-designed studies to support their efficacy have been conducted.

Development: These clinical guidelines are based on a review of the literature and the results of an AMN movement disorder study group survey.

Conclusions: Evidence suggests that nortriptyline, venlafaxine, paroxetine, and citalopram may be useful in treating depression in PD, although studies on paroxetine and citalopram

[☆] Please cite this article as: Peña E, Mata M, López-Manzanares L, Kurtis M, Eimil M, Martínez-Castrillo JC, et al. Antidepresivos en la enfermedad de Parkinson. Recomendaciones del grupo de trastornos del movimiento de la Asociación Madrileña de Neurología. Neurología. 2018;33:395–402.

^{☆☆} On behalf of the movement disorder study group of the Neurological Association of Madrid.

* Corresponding author.

E-mail address: epenal.pex@sanitas.es (E. Peña).

yield conflicting results. In clinical practice, however, selective serotonin reuptake inhibitors are usually considered the treatment of choice. Duloxetine may be an alternative to venlafaxine, although the evidence for this is less, and venlafaxine plus mirtazapine may be useful in drug-resistant cases. Furthermore, citalopram may be indicated for the treatment of anxiety, atomoxetine for hypersomnia, trazodone and mirtazapine for insomnia and psychosis, and bupropion for apathy. In general, antidepressants are well tolerated in PD. However, clinicians should consider the anticholinergic effect of tricyclic antidepressants, the impact of serotonin-norepinephrine reuptake inhibitors on blood pressure, the extrapyramidal effects of antidepressants, and any potential interactions between monoamine oxidase B inhibitors and other antidepressants.

© 2016 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

PALABRAS CLAVE

Antidepresivos;
Depresión;
Ansiedad;
Enfermedad de
Parkinson;
Efectos secundarios;
Mecanismos de acción

Antidepresivos en la enfermedad de Parkinson. Recomendaciones del grupo de trastornos del movimiento de la Asociación Madrileña de Neurología

Resumen

Introducción: El uso de antidepresivos está muy extendido en la enfermedad de Parkinson (EP), aunque existen pocos estudios de calidad que aclaren su eficacia.

Desarrollo: La metodología para esta guía clínica se ha basado en la revisión de la literatura y en la opinión de consenso del grupo de trastornos del movimiento de la AMN, recogida mediante una encuesta.

Conclusiones: Según la evidencia científica, nortriptilina, venlafaxina, paroxetina o citalopram podrían ser utilizados en el tratamiento de la depresión en la EP, aunque paroxetina y citalopram con resultados contradictorios. Sin embargo, en la práctica clínica, los inhibidores selectivos de la recaptación de serotonina suelen ser los fármacos de primera elección. Por otro lado, aunque con menor evidencia, duloxetina podría ser una alternativa a venlafaxina y la asociación de venlafaxina con mirtazapina podría ser útil en casos refractarios. Además, podemos considerar el uso de citalopram para la ansiedad, atomoxetina para el tratamiento de la hipersomnia diurna, trazodona y mirtazapina para el tratamiento del insomnio y la psicosis, y bupropión para el tratamiento de la apatía. En general, los antidepresivos son fármacos bien tolerados en la EP. No obstante, es necesario considerar el efecto anticolinérgico de los tricíclicos, el efecto sobre la presión arterial de los inhibidores de la recaptación de serotonina y noradrenalina, la capacidad de los antidepresivos para desarrollar síntomas extrapiramidales y tener precaución con la asociación de inhibidores de la monoaminooxidasa B.

© 2016 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Antidepressants are a heterogeneous group of drugs whose action primarily consists in the stimulation of 3 neurotransmitter systems (the dopaminergic, serotonergic, and noradrenergic systems). These drugs are widely used by neurologists. In Parkinson's disease (PD), they are prescribed to treat depression, anxiety, and other non-motor symptoms. [Table 1](#) lists the antidepressants that are most commonly used in daily practice and their main mechanisms of action.

Despite the high prevalence of non-motor symptoms in patients with PD (estimated at 3.6%-50% for anxiety¹ and 13%-50.1% for depression²), and their significant impact on patients' quality of life, they are often not adequately

treated: it is estimated that only 20% of patients with PD presenting with anxiety or depression receive any type of medical or psychological treatment for these symptoms.³ The basis of the problem is the shortage of high-quality studies into the efficacy of antidepressants for different indications in patients with PD and the consequent lack of any clear recommendations; as a result, neurologists often have to rely on little more than their own experience when selecting a drug.

Considering the issues described above, the Neurological Association of Madrid's movement disorder study group deemed it beneficial to establish a series of general recommendations on the use of antidepressants in patients with PD. We hope that these recommendations, based on the

Table 1 A selection of antidepressants used in PD and their main mechanisms of action.

Drug group	Antidepressants	Action mechanism
SSRIs	Citalopram Escitalopram Paroxetine Sertraline	Increase serotonin concentration in the synaptic cleft by inhibiting serotonin reuptake by the presynaptic membrane. Citalopram/escitalopram are the SSRIs with the least pronounced anticholinergic effect.
SNRIs	Venlafaxine Duloxetine	Increase serotonin and norepinephrine concentration in the synaptic cleft by inhibiting their reuptake by the presynaptic membrane.
NERIs	Atomoxetine	Increase norepinephrine concentration in the synaptic cleft by inhibiting norepinephrine reuptake by the presynaptic membrane.
NDRIs	Bupropion	Increase dopamine and norepinephrine concentration in the synaptic cleft by inhibiting their reuptake by the presynaptic membrane.
TCAs	Nortriptyline Amitriptyline	Increase serotonin and norepinephrine concentration in the synaptic cleft by inhibiting their reuptake by the presynaptic membrane. Strong anticholinergic effect.
Tetracyclic antidepressants	Mirtazapine	Increase serotonin and norepinephrine concentration in the synaptic cleft by inhibiting their reuptake by the presynaptic membrane. Antihistamine properties. Sedative and appetite stimulant effects.
SARIs	Trazodone	Antagonises the serotonin 5-HT _{2A} receptor; inhibits serotonin reuptake by the presynaptic membrane. Sedative effect; can have anxiolytic properties.
MAO inhibitors	Selegiline Rasagiline	Inhibit the action of monoamine oxidase enzymes, increasing the extracellular concentration of monoamines. Two subtypes: MAO-A inhibitors mainly affect serotonin and norepinephrine levels, and MAO-B inhibitors act on dopamine.

MAO: monoamine oxidase; NDRI: norepinephrine-dopamine reuptake inhibitor; NERI: norepinephrine reuptake inhibitor; SARI: serotonin antagonist and reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant.

available scientific evidence and our consensus opinion, may be of use to neurologists as a tool for decision-making in clinical practice.

Development

Methods

We performed a systematic search of the Medline database for published scientific articles, using the search terms "Parkinson's disease" and "antidepressants", with special emphasis on papers published in the last 10 years. The bibliographical references of the articles found using this approach were used as an additional source of information. In addition to the literature review, 12 neurologists specialising in the field of movement disorders (members of our study group) were sent a survey on the use of antidepressants in daily clinical practice.

We used the levels of evidence and degrees of recommendation proposed by the American Academy of Neurology⁴⁻⁶ (Table 2) to assess the papers selected.

Usefulness of antidepressants in patients with Parkinson's disease

Few well-designed clinical trials have assessed the efficacy of antidepressants in treating depression in patients with PD; not all of these report positive results (Table 3). The only drugs that achieved statistically significant improvements in these trials were nortriptyline, desipramine, venlafaxine, paroxetine, and citalopram⁷⁻⁹; results were conflicting for the latter 2 drugs.^{7,10} Efficacy was not demonstrated for atomoxetine or sertraline.^{11,12} A 2011 meta-analysis concluded that tricyclic antidepressants (TCA) may be the most efficacious treatment for depression in patients with PD, followed by serotonin-norepinephrine reuptake inhibitors (SNRI); selective serotonin reuptake inhibitors (SSRI) were found to be the least efficacious.¹³ The Movement Disorder Society's¹⁴ recommendations for the treatment of non-motor symptoms of PD, also published in 2011, conclude that TCAs are probably efficacious for depression in patients with PD, but that there was not sufficient evidence supporting treatment with the remaining drug types. In fact, some reviews have recommended TCAs as the treatment of choice, at least in young patients without cognitive

Table 2 Levels of evidence and recommendations according the American Academy of Neurology classification.

Level of evidence	Recommendations
Class I. Randomised, controlled clinical trial meeting the following conditions: concealed allocation; clearly defined primary outcomes and inclusion/exclusion criteria; adequate accounting for drop-outs	A = established as effective, ineffective, or harmful (at least 2 class I studies are required)
Class II. Randomised, controlled clinical trial lacking at least one of the requirements listed above	B = probably effective, ineffective, or harmful (one class I or 2 class II studies are required)
Class III. Any other controlled trial	C = possibly effective, ineffective, or harmful (one class II or 2 class III studies are required)
Class IV. Other studies, including consensus or expert opinion	U = inadequate or conflicting data

Table 3 Double-blind, randomised, placebo-controlled clinical trials on the efficacy of various antidepressants in treating depression in patients with PD.

Study	Year	Antidepressant	Patients (n)	Follow-up (weeks)	Results
Wermuth et al. ¹⁰	1998	Citalopram	37	8	No difference vs placebo
Leentjens et al. ¹¹	2003	Sertraline	12	10	No difference vs placebo
Devos et al. ⁸	2008	Citalopram Desipramine	48	4	Both drugs showed greater efficacy than placebo.
Menza et al. ⁷	2009	Paroxetine Nortriptyline	52	8	Paroxetine showed no difference vs placebo. Nortriptyline showed greater efficacy than placebo.
Weintraub et al. ¹²	2010	Atomoxetine	55	8	No difference vs placebo
Richard et al. ⁹	2012	Paroxetine Venlafaxine	115	12	Both drugs showed greater efficacy than placebo.

impairment.¹⁵ None of these recommendations take into account a later study by Richard et al.⁹ into paroxetine and venlafaxine, which found statistically significant improvements over placebo for both drugs. A recent meta-analysis which did include that study concluded that SSRIs specifically were associated with a significant improvement in depression in patients with PD, casting doubt over the efficacy of TCAs.¹⁶ This attests to the controversy surrounding the issue, which is far from being resolved.

Other antidepressants may also be useful for treating depression in patients with PD, although there is less evidence supporting their use. A non-comparative longitudinal study into duloxetine demonstrated statistically significant improvements in patients' scores on the Hamilton Rating Scale for Depression, compared to baseline scores¹⁷; the drug may therefore represent an alternative to venlafaxine. Co-administration with mirtazapine has been shown to increase the efficacy of venlafaxine in treating depression.¹⁸ Although no study has evaluated this drug combination

in patients with PD, it may also be taken into account when treating these patients, at least those with refractory depression. Finally, it would be valuable to assess the antidepressant properties of monoamine oxidase B (MAO-B) inhibitors, which are widely used to treat motor symptoms of PD. In a recent placebo-controlled clinical trial, 1 mg rasagiline did not significantly improve symptoms of depression in patients with PD.¹⁹ However, a non-comparative longitudinal study found that 2 mg rasagiline was associated with a significant improvement in depression compared to baseline, independently of the improvement in motor symptoms.²⁰ Another non-comparative study found that depression significantly improved in patients with PD following administration of selegiline in combination with another antidepressant.²¹ These findings are of great interest given the current research into combination therapy with selegiline and other antidepressants to treat refractory depression.²² However, evidence on this subject is still very limited, and general recommendations cannot

be made on the use of MAO-B inhibitors in this field. Finally, although they are not addressed in this review, it is worth noting the antidepressant effect of dopamine agonists, particularly pramipexole, as has been demonstrated in a class I study.²³ Neurologists should consider using these drugs, perhaps even before administering specifically antidepressant drugs.² Other treatments described include electroconvulsive therapy, transcranial magnetic stimulation, and psychotherapy.²

The effect of antidepressants on anxiety in patients with PD has only been evaluated by one non-comparative prospective study, and addressed as a secondary outcome measure in several other clinical trials.^{7–9,12,24} These studies found that only TCAs and citalopram achieved statistically significant improvements.^{7,8,24} Conversely, efficacy was not demonstrated in paroxetine, venlafaxine, or atomoxetine.^{9,12} Antidepressants may be indicated for other conditions in patients with PD. One study points to the potential efficacy of atomoxetine for treating daytime sleepiness.¹² Further research is needed before recommendations can be made in this regard. Cases have also been described of mirtazapine achieving positive results in the treatment of psychosis in patients with PD.^{25–27} One comparative study of trazodone and haloperidol also reports the efficacy of trazodone in treating psychosis, although this study included patients with dementia, not PD.²⁸ The sedative effect of these drugs may also make them effective as a treatment for insomnia.¹ Finally, bupropion is thought to be useful in treating apathy associated to various neurodegenerative diseases, although evidence of this remains limited.^{29,30}

Tolerability of antidepressants in patients with Parkinson's disease

Antidepressants are generally well tolerated by patients with PD.^{13,14} However, TCAs should be used with caution in patients with urinary retention, closed-angle glaucoma, or cardiovascular diseases due to their anticholinergic effect.¹⁴ These drugs may also contribute to the development of psychosis, sedation, and daytime sleepiness in patients with PD, as well as cognitive dysfunction and delusion in cases where PD is associated with dementia.¹⁴ Arterial hypertension is a frequent side-effect of SNRIs; Richard et al.⁹ report hypertension in 4 of 34 patients receiving venlafaxine, compared to only one of 42 in the group of patients receiving paroxetine and no patients in the control group. SNRIs must therefore be used with caution in patients with poorly controlled hypertension or cardiovascular comorbidities.

Extrapyramidal adverse effects of antidepressants

All classes of antidepressant, particularly SSRIs and SNRIs, have been associated with extrapyramidal adverse effects.³¹ These adverse reactions appear to be less frequent in TCAs.³² Previous treatment with neuroleptics, lithium, or oestrogens seems to favour onset of extrapyramidal adverse effects in patients receiving TCAs.³² Isolated cases have also been reported of bupropion-induced parkinsonism.^{33,34}

A review of extrapyramidal symptoms in patients treated with serotonergic antidepressants, which included

86 articles published between 1998 and 2015 and a total of 91 patients, found greater incidence of these symptoms in patients younger than 65 years old (78%) and in women (57% vs 43% in men).³¹ In addition to this, 22% of patients were also receiving drugs with potential extrapyramidal effects, such as antipsychotics.³¹ The adverse reactions described include akathisia, dystonia, parkinsonism, and dyskinesia.³¹ At normal doses, symptoms generally appeared within the first 30 days of treatment; in 67% of cases, onset occurred during the first 7 days.³¹ The exception to this was dyskinesia, which was characterised by a more delayed onset (later than 30 days in 55.6% of patients and later than 90 in 44%).³¹ The drugs most frequently associated with this type of adverse effect were citalopram/escitalopram (22%), fluoxetine (20.9%), sertraline (15.4%), venlafaxine (12.1%), and duloxetine (5.5%).³¹ Of the 19 cases of antidepressant-associated onset or worsening of parkinsonism, 15 (79%) were due to SSRIs, 6 of which (40%) were associated with sertraline.³¹ Of the 4 cases of SNRI-associated parkinsonism, 2 were caused by venlafaxine and 2 by milnacipran; no cases were due to duloxetine use. Fifty-eight per cent of patients were older than 65 years old; slightly over half were women.³¹

A recent meta-analysis of patients with PD, including only randomised controlled trials, found few cases of adverse effects on motor function; these were isolated and showed no significant differences compared to placebo.¹⁶ One of the studies included, comparing citalopram and desipramine against placebo, reported that one of the 15 patients receiving citalopram experienced worsening of bradykinesia to the extent that treatment was suspended.⁸ In the same study, 2 patients receiving the placebo, one receiving citalopram, and one patient receiving desipramine, displayed mild, transient tremor.⁸ Another study reported that PD symptoms worsened in a patient treated with citalopram, although motor function was unaffected.¹⁰ Finally, clinical trials on sertraline,¹¹ nortriptyline,⁷ venlafaxine,⁹ and paroxetine^{7,9} reported no significant extrapyramidal adverse effects. However, in the Richard et al.⁹ study, tremor was observed in 7 patients from the treatment group (16% of those treated with paroxetine and 20% of those treated with venlafaxine) and 3 from the placebo group. In fact, one of the patients receiving venlafaxine dropped out of the study due to this symptom.⁹ Finally, a study by Bonuccelli et al.¹⁷ found no worsening of motor symptoms in patients receiving duloxetine.

Two papers specifically evaluated the effect of antidepressant treatment on motor symptoms in patients with PD.^{35,36} Dell'Agnello et al.³⁵ performed a prospective study into the incidence of extrapyramidal adverse effects of 4 SSRIs (citalopram, sertraline, fluvoxamine, and fluoxetine) in a group of 62 patients with PD presenting with stable motor symptoms. The patients were assessed with the UPDRS at baseline and at 1, 3, and 6 months after treatment onset. Patients received either 50 mg/day sertraline, 20 mg/day citalopram, 20 mg/day fluoxetine, or 150 mg/day fluvoxamine. No significant differences were observed in UPDRS scores. Two patients in the fluvoxamine group and 2 in the fluoxetine group displayed a worsening of tremor.

Kulisevsky et al.³⁶ performed a 6-month prospective, naturalistic study, including 374 patients with PD associated with depression and undergoing treatment with sertraline

(66 ± 29.8 mg/day). According to UPDRS scores, treatment had no significant adverse effects on motor symptoms; improvements were even observed. Three patients displayed worsening of tremor and 2 displayed new-onset tremor.

To summarise, though infrequent, extrapyramidal symptoms can be induced by antidepressants at normal doses and should be considered when prescribing these drugs. Although antidepressants do not generally have a significant negative effect on motor function in patients with PD, isolated cases may occur, with tremor being the most frequent symptom.

The issue of combining monoamine oxidase B inhibitors and other antidepressants

Prescribing MAO-B inhibitors in combination with other antidepressants is a controversial subject due to the risk of serotonin syndrome, which can be severe and potentially fatal. The summary of product characteristics for selegiline contraindicates its use in combination with other antidepressants. The summary of product characteristics for rasagiline contraindicates concomitant use of other MAO-B inhibitors, and recommends avoidance of fluoxetine and fluvoxamine and caution with all other antidepressants. Richard et al.³⁷ performed a study on selegiline use in 4468 patients, establishing an incidence of 0.24% for serotonin syndrome, with severe episodes having an incidence of 0.04%. Nonetheless, other recent studies into the combination of rasagiline with SSRIs, SNRIs, TCAs, or other antidepressants, with a total of 978 patients, did not find any cases of serotonin syndrome,³⁸ significant increases in unexpected adverse effects,^{39,40} or an increase in drop-out rates as a result of the combination of these drugs.⁴⁰

Clinical practice

Seven of the 12 neurologists participating in our survey preferred SSRIs, particularly escitalopram, citalopram, sertraline, and paroxetine, as the drug of first choice to treat depression in patients with PD. This choice was justified by good tolerance, few drug–drug interactions, and suitability for patients with comorbidities. SNRIs, particularly duloxetine, were the antidepressants of choice for 4 participants; only 2 neurologists opted for TCAs, with amitriptyline being the most frequently used drug in this case. Efficacy was one of the motives given for this preference. However, there was a tendency to avoid prescribing SNRIs and TCAs to patients of advanced age or with associated cognitive impairment or other comorbidities; in these cases, SSRIs were preferred, and particularly those with a less pronounced anticholinergic effect. Finally, 2 neurologists selected other types of antidepressants as their first choice of drug, with mirtazapine receiving particular emphasis.

Ten participants selected SNRIs as the drug of second choice, particularly displaying a preference for duloxetine over venlafaxine. The other options selected were more diverse: TCAs, SSRIs, mirtazapine (either alone or in combination with other drugs), bupropion, and trazadone.

Nine respondents reported using antidepressants to treat other non-motor symptoms of PD. This also influenced drug

Table 4 Typical doses prescribed in clinical practice.

Drug	Dose (mg/day)
Citalopram	10-40
Escitalopram	10-20
Sertraline	50-100
Paroxetine	20
Venlafaxine	37.5-150
Duloxetine	30-90
Amitriptyline	10-75
Nortriptyline	10-75
Mirtazapine	15-30
Trazodone	50-300
Bupropion	150-300
Atomoxetine	40-80
Selegiline	5-10
Rasagiline	1
Quetiapine	25-200
Clozapine	12.5-100

choice. Frequently mentioned examples were bupropion for apathy, mirtazapine for insomnia and to stimulate appetite, trazodone for insomnia and mild psychosis, duloxetine for pain, and amitriptyline for sialorrhoea. Combination of an antidepressant with quetiapine or clozapine was also frequent for patients with depression associated with psychotic symptoms.

Regarding alternative treatments, 9 survey respondents mentioned the antidepressant effects of such other drugs as MAO-B inhibitors and pramipexole. Seven mentioned non-pharmacological treatments, including psychotherapy, occupational therapy, and physical exercise. Finally, 10 participants reported prescribing antidepressants to patients also receiving MAO-B inhibitors, observing no clinically significant adverse effects. The doses most frequently used in clinical practice are shown in [Table 4](#).

Conclusions

Based on the available scientific evidence, nortriptyline, venlafaxine, paroxetine, and citalopram may be used to treat depression in patients with PD, although conflicting results were found for the latter 2 drugs. In clinical practice, on the other hand, SSRIs are usually the drugs of first choice, as they are perceived as being well tolerated, having few drug–drug interactions, and being suitable for patients with comorbidities. Duloxetine may serve as an alternative to venlafaxine, and venlafaxine combined with mirtazapine may be useful in cases of refractory depression; the scientific evidence supporting this is more limited, however. Neurologists should also consider prescribing citalopram to treat anxiety; atomoxetine for excessive daytime sleepiness; trazodone and mirtazapine for insomnia, psychosis, and agitation; and bupropion for apathy. [Table 5](#) shows the levels of evidence for different indications.

Antidepressants are generally well tolerated by patients with PD. Nonetheless, depending on each patient's clinical characteristics, we must take into account the anticholinergic effect of TCAs, SNRIs' effect on blood pressure, and the

Table 5 Levels of evidence and grades of recommendation of different antidepressants for different indications in patients with PD.

	Drug (level of evidence + level of recommendation)
Depression	Paroxetine (class I, recommendation U) Citalopram (class I, recommendation U) Venlafaxine (class I, recommendation B) Duloxetine (class III, recommendation U) Nortriptyline (class I, recommendation B) Venlafaxine + mirtazapine (class IV, recommendation U) MAO-B inhibitors (class IV, recommendation U)
Anxiety	Citalopram (class III, recommendation U) Nortriptyline (class IV, recommendation U)
Insomnia, psychosis, night-time agitation	Mirtazapine (class IV, recommendation U) Trazodone (class IV, recommendation U)
Excessive daytime sleepiness	Atomoxetine (class IV, recommendation U)
Apathy	Bupropion (class IV, recommendation U)

Table 6 Recommendations for the pharmacological treatment of depression in patients with PD according to clinical profile.

	Recommended treatment
Young patient without cognitive impairment	SSRIs (also SNRIs and TCAs)
Elderly patient with comorbidities and potential for drug-drug interactions	SSRIs with less pronounced anticholinergic effect (avoid SNRIs and TCAs)
Patient with cognitive impairment and psychosis	Trazodone/antidepressant + quetiapine or clozapine
Patient with anxiety	SSRIs (citalopram)
Patient with insomnia	Mirtazapine/trazodone
Patient with chronic pain	Duloxetine
Overweight patient	Avoid mirtazapine
Patient with arterial hypertension	Avoid SNRIs
Patient with dysautonomia	Avoid drugs with an anticholinergic effect

potential for antidepressant use to lead to the appearance of extrapyramidal symptoms. The evidence available in the literature appears to indicate the safety of co-prescribing MAO-B inhibitors, particularly rasagiline, with other antidepressants. However, caution should be exercised given the severity of the potential adverse effects. The instructions in the summary of product characteristics should always be followed. Further study is needed in this field.

Given the lack of additional studies and the potential for adverse effects in patients with PD, the patient's clinical profile is of great importance in selecting an antidepressant. Based on the publications available in the literature and our own survey results, we have made a series of recommendations for the treatment of various common clinical situations, which we present in [Table 6](#).

In conclusion, further evidence is needed to clarify the role of antidepressant use in patients with PD, in treating both depression and such other conditions as anxiety, insomnia, hypersomnia, nocturnal psychosis, and apathy.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Djamshidian A, Friedman JH. Anxiety and depression in Parkinson's disease. *Curr Treat Options Neurol*. 2014;16:285.
2. Aarstrand D, Pählhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. *Nat Rev Neurol*. 2011;8:35–47.
3. Troeung L, Egan SJ, Gasson N. A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. *PLOS ONE*. 2013;8:e79510.
4. French J, Gronseth G. Lost in a jungle of evidence: we need a compass. *Neurology*. 2008;71:1634–8.
5. Gronseth G, French J. Practice parameters and technology assessments: what they are, what they are not, and why you should care. *Neurology*. 2008;71:1639–43.
6. Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. *Neurology*. 2008;72:8–10.
7. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. *Neurology*. 2009;72:886–92.
8. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. *Mov Disord*. 2008;23:850–7.
9. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, et al. A randomized, double-blind, placebo-controlled

- trial of antidepressants in Parkinson disease. *Neurology*. 2012;78:1229–36.
10. Wermuth L, Sørensen P, Timm B. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo-controlled trial. *Nord J Psychiatry*. 1998;52:163–9.
 11. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. *Int J Geriatr Psychiatry*. 2003;18:552–4.
 12. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. *Neurology*. 2010;75:448–55.
 13. Liu J, Dong J, Wang L, Su Y, Yan P, Su Sh. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. *PLOS ONE*. 2013;8:e76651.
 14. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. *Mov Disord*. 2011;3 Suppl:S42–80.
 15. De Rezende Costa FH, Zuma AL, Maultasch H, Hack D. Depression in Parkinson's disease: diagnosis and treatment. *Arq Neuropsiquiatr*. 2012;70:617–20.
 16. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord*. 2015;21:833–42.
 17. Bonuccelli U, Meco G, Fabbri G, Tessitore A, Pierantozzi M, Stocchi F, et al. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. *Expert Opin Pharmacother*. 2012;13:2269–80.
 18. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. *Am J Psychiatry*. 2010;167:281–8.
 19. Barone P, Santangelo G, Morgante L, Onofri M, Meco G, Abbruzzese G, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *Eur J Neurol*. 2015;22:1184–91.
 20. Korzhounov A, Winter Y, Rössy W. Combined beneficial effect of rasagiline on motor function and depression in de novo PD. *Clin Neuropharmacol*. 2012;35:121–4.
 21. Steur EJ, Ballering L. Moclobemide and selegiline in the treatment of depression in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1997;63:547–58.
 22. Thomas SJ, Shin M, McInnis MG, Bostwick JR. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. *Pharmacotherapy*. 2015;35:433–49.
 23. Barone P, Poewe W, Albrecht S, Debievre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2010;9:573–80.
 24. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. *J Neuropsychiatry Clin Neurosci*. 2004;16:315–9.
 25. Godschalx-Dekker JA, Siegers HP. Reduction of parkinsonism and psychosis with mirtazapine: a case report. *Pharmacopsychiatry*. 2014;47:81–3.
 26. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. *Psychogeriatrics*. 2013;13:103–7.
 27. Nagata T, Shinagawa S, Tagai K, Nakayama K. A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. *Psychogeriatrics*. 2013;25:199–201.
 28. Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. *Am J Geriatr Psychiatry*. 1997;5:60–9.
 29. Krishnamoorthy A, Craufurd D. Treatment of apathy in Huntington's disease and other movement disorders. *Curr Treat Options Neurol*. 2011;13:508–19.
 30. Corcoran C, Wong ML, O'Keane V. Bupropion in the management of apathy. *J Psychopharmacol*. 2004;18:133–5.
 31. Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. *Ann Pharmacother*. 2015;49:1136–52.
 32. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. *Eur Neuropharmacol*. 1997;7:207–12.
 33. Grandas F, López-Manzanares L. Bupropion-induced parkinsonism. *Mov Disord*. 2007;22:1830–1.
 34. Cheng WC, Liu CM, Hsieh MH, Hwang TJ. Bupropion-related parkinsonism and dystonia. *J Clin Psychopharmacol*. 2009;29:616–8.
 35. Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, D'Avino C, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. *Clin Neuropharmacol*. 2001;24:221–7.
 36. Kulisevsky J, Pagonarraga J, Pascual-Sedano B, Gironell A, García-Sánchez C, Martínez-Corral M. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. *Eur J Neurol*. 2008;15:953–9.
 37. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. *Neurology*. 1997;48:1070–7.
 38. Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J, The STAC-CATO study investigators. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). *Pharmacotherapy*. 2014;34:1250–8.
 39. Smith KM, Eyal E, Weintraub D, for the ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study. Effects on nonmotor symptoms and tolerability. *JAMA Neurol*. 2015;72:88–95.
 40. Panisset M, Schwied S, Ondo W, Fitzer-Attas Ch, Chen JJ. Safety of concomitant therapy with rasagiline and antidepressants in Parkinson's disease. *Mov Disord*. 2007;22:340.